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ABSTRACT
Objective To assess the 1-year efﬁcacy and safety of a
regimen of tocilizumab plus methotrexate or placebo,
which was augmented by a treat-to-target strategy from
week 24.
Methods ACT-RAY was a double-blind, 3-year trial.
Adults with active rheumatoid arthritis despite
methotrexate were randomised to add tocilizumab to
ongoing methotrexate (add-on strategy) or to switch to
tocilizumab plus placebo (switch strategy). Tocilizumab
8 mg/kg was administered every 4 weeks. Conventional
open-label disease-modifying antirheumatic drugs
(DMARDs) other than methotrexate were added at week
24 or later in patients with DAS28>3.2.
Results 556 patients were randomised; 85%
completed 52 weeks. The proportion of patients
receiving open-label DMARDs was comparable in the
add-on (29%) and switch (33%) arms. Overall, week 24
results were maintained or further improved at week 52
in both arms. Some endpoints favoured the add-on
strategy. Mean changes in Genant-modiﬁed Sharp scores
were small; more add-on (92.8%) than switch patients
(86.1%) had no radiographic progression. At week 52,
comparable numbers of patients had antidrug antibodies
(ADAs; 1.5% and 2.2% of add-on and switch patients,
respectively) and neutralising ADAs (0.7% and 1.8%).
Rates of serious adverse events and serious infections
per 100 patient-year (PY) were 11.3 and 4.5 in add-on
and 16.8 and 5.5 in switch patients. In patients with
normal baseline values, alanine aminotransferase
elevations >3× upper limit of normal were observed in
11% of add-on and 3% of switch patients.
Conclusions Despite a trend favouring the add-on
strategy, these data suggest that both tocilizumab add-
on and switch strategies led to meaningful clinical and
radiographic responses.
INTRODUCTION
The goal of rheumatoid arthritis (RA) therapy is to
reduce or prevent functional impairment and struc-
tural damage that can occur over a patient’s life-
time. Long-term control is often best achieved
through the adaptation of treatment based on
disease activity (treat-to-target).1 Typical treatment
modiﬁcations include the addition of conventional
disease-modifying antirheumatic drugs (DMARDs)
to pre-existing therapy, the addition of a biologic to
a conventional DMARD or a switch from a conven-
tional DMARD to a biologic therapy.
When disease control is inadequate with the ﬁrst
traditional DMARD, typically methotrexate,
patients will frequently receive biologic therapy in
addition to or instead of methotrexate.2 In clinical
practice, approximately one-third of patients with
RA are being treated with biologic monotherapy,3–5
often because of tolerability issues with methotrex-
ate.6–8 One such biologic therapy is tocilizumab, a
humanised antihuman interleukin-6 (IL-6) receptor
monoclonal antibody.9
Tocilizumab is efﬁcacious and generally well toler-
ated in a wide range of patients with RAwhen given as
either monotherapy10 or in combination with metho-
trexate11 and other DMARDs.12 Long-term studies
have demonstrated that tocilizumab can reduce the
signs and symptoms of RA for several years in combin-
ation with a conventional DMARD and as monother-
apy.10 13–15 Further, tocilizumab, in combination with
methotrexate, has been shown to inhibit radiographic
progression for up to 3 years in patients with an inad-
equate response to methotrexate.14
ACT-RAY is a 3-year, phase 3b, randomised,
double-blind clinical trial. The ﬁrst 24 weeks of
ACT-RAY assessed the efﬁcacy and safety of adding
tocilizumab to ongoing methotrexate (add-on strat-
egy) versus switching to tocilizumab monotherapy
(switch strategy) in patients with moderate to
severe active RA experiencing an inadequate
response to methotrexate.16 The primary efﬁcacy
analysis of the study at week 24 did not succeed at
demonstrating superiority of the add-on over the
switch strategy, suggesting that switching to tocili-
zumab monotherapy might be a valuable treatment
strategy for patients for whom methotrexate is con-
traindicated or poorly tolerated.16
From week 24 to year 3, ACT-RAY employed a
treat-to-target strategy. During weeks 24–52,
patients continued on tocilizumab therapy with
blinded methotrexate or placebo (PBO), but open-
label conventional DMARDs were added based on
disease activity, with the ultimate objective to
induce clinical remission during the course of the
study. This article reports on the main objectives of
the 52-week analyses, which were to evaluate the
sustainability of the response observed at week 24
and to further evaluate the treatment strategies in
terms of clinical activity, structural damage,
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immunogenicity and changes in concomitant therapies (all sec-
ondary study objectives). Full assessment of treatment adapta-
tion strategies (step-up and step-down) will occur after year 2.
PATIENTS AND METHODS
This report covers the planned analysis for the ﬁrst 52 weeks of
a 3-year, double-blind, PBO-controlled, parallel-group clinical
trial (NCT00810199, EudraCT No. 2008-001847-20). The
study was approved by the appropriate institutional review
boards/ethics committees and was conducted in accordance with
International Conference on Harmonisation Good Clinical
Practice and local regulations. All patients provided written
informed consent for the 3 years of the ACT-RAY study.
Patients and methods have been previously described.16 Brieﬂy,
patients had conﬁrmed RA according to the 1987 American
College of Rheumatology (ACR) classiﬁcation criteria with Disease
Activity Score based on 28 joints-erythrocyte sedimentation rate
(DAS28-ESR) >4.4 at baseline, despite a stable methotrexate dose
of at least 15 mg/week for >6 weeks and radiographic evidence of
RA-related joint erosions. Major exclusion criteria included previ-
ous use of biologics and any conventional DMARD treatment
other than methotrexate during the month preceding baseline
visit. At randomisation, patients either added open-label tocilizu-
mab 8 mg/kg intravenously every 4 weeks to their existing metho-
trexate (add-on strategy) or were switched to tocilizumab alone
(switch strategy; with PBO). Until week 24, these treatments were
maintained except for safety reasons.
Treat-to-target and concomitant RA treatments
Following the primary endpoint analysis at week 24, treatment
was intensiﬁed based on individual disease activity while blind-
ing was maintained in both study groups. At week 24, if a
patient had a DAS28 >3.2, an open-label conventional
DMARD (sulfasalazine, leﬂunomide, chloroquine, hydroxy-
chloroquine, parenteral gold or azathioprine; choice and dose at
investigator’s discretion) was added. At week 36, if a patient still
had a DAS28 score >3.2 with the added DMARD, the patient
was moved to the maintenance-regimen arm with the option of
adding an additional conventional DMARD at the investigator’s
discretion. Patients in the maintenance arm did not undergo sys-
tematic step-up or step-down therapy but were treated as per
the investigator’s discretion. Tocilizumab and/or DMARD treat-
ment was reduced or temporarily interrupted in patients with
alanine aminotransferase (ALT) or aspartate aminotransferase
(AST) values >1 to 3× the upper limit of normal (ULN) and
discontinued for persistent increases >3× ULN (see online sup-
plementary table S2 for risk mitigation strategy).
Oral corticosteroids (≤10 mg/day prednisone or equivalent)
and non-steroidal anti-inﬂammatory drug (NSAIDs) were per-
mitted, provided that doses remained stable for at least 25 of
28 days prior to the start of study treatment. Alterations in
NSAID dose were not recommended during the study, particu-
larly during the ﬁrst 24 weeks. The corticosteroid dose could
not be changed during the ﬁrst 24 weeks of the study. From
week 24, if DAS28 ≤3.2, corticosteroid treatment could be
reduced by 2.5 mg/day prednisone-equivalents at week 24 or
any visit thereafter; however, the dose may not have been
reduced to <5 mg/day during the ﬁrst year or be increased back
to a level above the patient’s baseline dose.
Collected patient data and assessments
Efﬁcacy, radiographic and safety assessments
Clinical and laboratory data were collected every 4 weeks.16
Radiographs of hands/wrists and feet were obtained at baseline,
week 24 and week 52 and were assessed by applying the
Genant-modiﬁed Sharp score (GSS) from two independent
readers (Perceptive Informatics Medical Imaging Services,
Berlin, Germany) who were blinded to treatment assignment,
chronological order of radiographs and patient’s clinical status.
The smallest detectable change (SDC)17 for GSS was computed
based on the observed SD of difference between the X-ray
readers; three readers in total participated in the campaign.
Immunogenicity
Following a regulatory request regarding the tocilizumab devel-
opment programme, immunogenicity testing was introduced to
ACT-RAY while the study was ongoing. Patients were tested for
antidrug and neutralising antibodies using available samples
from baseline, week 24 and week 52 (or withdrawal visit not
later than week 52). Samples were analysed using a screening
assay ﬁrst. If positive for antitocilizumab antibodies, a neutralis-
ing assay was performed to test for the ability of those anti-
bodies to inhibit the activity of tocilizumab. The cut-off for
assay positivity was determined using baseline sera from
ACT-RAY patients.
Statistical analysis
The target sample size was 235 patients per arm, resulting from
power considerations around the primary analysis of the week
24 DAS28 remission rate.16 For this and similar endpoints,
logistic regression models were employed including region and
baseline DAS28 or the respective baseline values (eg, CDAI or
radiographic scores), with supportive Cochran–Mantel–
Haenszel tests stratiﬁed for the same parameters. Analysis of
covariance models with similar adjustments was used to
compare continuous outcome measures. For the analyses pre-
sented here, statistical signiﬁcance was declared for p values
<0.05 and no correction for multiplicity was employed.
Efﬁcacy was analysed in the intention-to-treat (ITT) popula-
tion using non-responder imputation for categorical variables
(eg, DAS28 remission, ACR response and radiographic progres-
sion). The primary endpoint has been previously reported.16
Efﬁcacy endpoints were analysed in accordance with the
European League Against Rheumatism (EULAR)/ACR collabora-
tive recommendations for reporting RA disease activity in clin-
ical trials18 and included the mean change in DAS28-ESR,
ACR20/50/70/90 response and ACR core components.
Radiographic endpoints included changes from baseline in total
GSS, erosion and joint space narrowing scores, and the propor-
tion of patients with no radiographic progression (progression
deﬁned as change in GSS >1.5 for this speciﬁc reading cam-
paign). The means were adjusted for region, baseline DAS28
and GSS, and the 52-week analysis used linear extrapolation if
the week 24 assessment was evaluable. Safety endpoints
included the incidence of adverse events (AEs), serious adverse
events (SAEs), serious infections (SIs) and speciﬁc laboratory
abnormalities, which were analysed in the safety population (all
treated patients with at least one postdose assessment of safety,
analysed according to the received treatment).
RESULTS
Patient ﬂow and baseline characteristics
Figure 1 summarises the patient disposition through 52 weeks.
In total, 556 patients were recruited, exceeding the target of
470 patients. Of the 556 patients, 509 (92%) completed the
ﬁrst 24 weeks of the trial and 472 (85%) completed 52 weeks.
More patients discontinued the study due to a lack of efﬁcacy in
the switch arm (12 patients) versus the add-on arm (5 patients).
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Both patient groups were well matched for baseline character-
istics, except for a difference in GSS (which did not affect out-
comes; table 1).
Clinical efﬁcacy
Sustainability of therapeutic response
Table 2 summarises the efﬁcacy results by treatment group at
weeks 24 and 52, and key measures are depicted over time in
ﬁgure 2B–D. The improvements in signs and symptoms of RA
achieved by week 24 were maintained or further improved up to
week 52 in both the add-on and the switch groups. Overall, no
clinically relevant difference between the two groups was
observed. However, some results favoured the add-on strategy, as
the percentage of patients with DAS28 remission (DAS28 <2.6,
45.5% vs 36.6%), the change in patient’s global assessment of
pain, the change in erosion score and the percentage of patients
with no progression in GSS showed statistically signiﬁcant differ-
ences in favour of the add-on strategy. Other study endpoints,
including mean change in DAS28, did not result in statistically sig-
niﬁcant differences between the study arms.
Measures speciﬁcally tracking the sustainability of response
were also examined. Sustained ACR20 response was deﬁned as at
least six consecutive visits during a 1-year period in which a
patient had an ACR20 response. At week 52, 138 patients
(49.8%) and 131 patients (47.5%) from the add-on group and
switch groups, respectively, achieved a sustained ACR20 response
(p=0.5948). The percentage of patients in the add-on group who
achieved sustained low-disease activity state (DAS28≤3.2 at three
or more consecutive visits) was similar to that in the switch group
(46.9% vs 41.3%, respectively; p=0.171). Further, the percentage
of patients in the add-on group who achieved sustained DAS28
remission (DAS28<2.6 at three or more consecutive visits) was
similar to that in the switch group (28.5% vs 25.4%, respectively;
p=0.351).
Structural outcomes
At 52 weeks, the majority of patients exhibited no or minimal
progression of structural damage (ﬁgure 3C). There was no stat-
istically signiﬁcant intergroup difference in mean change from
baseline at week 24 or week 52 for the mean total GSS or the
joint space narrowing score (table 2 and ﬁgure 2A). The
adjusted mean change in erosion score was −0.09 for add-on
patients and 0.25 for switch patients (p=0.001), which fol-
lowed a statistically signiﬁcant difference at week 24 (table 2
and ﬁgure 2B). The SDC from baseline in GSS was 1.5, indicat-
ing a high agreement of the readings, therefore allowing for
detection of changes from baseline <−1.5 and >1.5. When
radiographic progression was deﬁned as any change in GSS
>SDC, 92.8% of add-on patients and 86.1% of switch patients
did not exhibit radiographic progression at week 52 (p=0.016)
(ﬁgure 3B). When the cut-off for radiographic progression was
deﬁned as change in GSS ≥ 0, 68.8% of add-on patients and
Table 1 Baseline characteristics
Add-on
(N=277)
Switch
(N=276)
Women, n (%) 227 (81.9) 217 (78.6)
Age (years), mean (SD) 53.0 (13.4) 53.6 (11.9)
Patients aged ≥65 years, n (%) 53 (19.1) 52 (18.8)
BMI, kg/m², mean (SD) 26.3 (5.20) 26.5 (5.14)
Duration of RA (years), mean (SD) 8.2 (8.0) 8.3 (8.4)
Categorical duration of RA (years), n (%):
<2 51 (18.4) 66 (23.9)
≥2 to <5 76 (27.4) 68 (24.6)
≥5 to <10 66 (23.8) 63 (22.8)
≥10 84 (30.3) 79 (28.6)
Swollen joint count, mean (SD) 14.4 (8.9) 15.3 (10.2)
Tender joint count, mean (SD) 25.8 (13.9) 26.6 (15.2)
DAS28-ESR, mean (SD) 6.33 (0.98) 6.36 (1.00)
HAQ-DI, mean (SD) 1.46 (0.65) 1.48 (0.60)
Fatigue,* n (%) 117 (75.0) 110 (73.3)
Genant-modified Sharp score, mean (SD) 30.8 (32.2) 37.2 (40.6)
MTX dose, mg/week, mean (SD) 16.1 (4.4) 16.3 (4.2)
MTX dose, mg/week, median 15.0 15.0
Number of previous DMARDs (including MTX
prior to study entry), mean (SD)
1.9 (1.1) 1.9 (1.0)
Oral steroid use, n (%) 140 (50.5) 140 (50.7)
Rheumatoid factor positive,† n (%) 55 (66.3) 41 (64.1)
Anti-CCP positive,† n (%) 68 (81.9) 49 (76.6)
*Assessed by the proportion of patients answering ‘yes’ to question 21 of the
Rheumatoid Arthritis Quality of Life questionnaire (‘I feel tired whatever I do’).
†Of 147 patients (27%) with available retrospective data.
BMI, body mass index; CCP, anticyclic citrullinated peptide; DAS28-ESR, Disease
Activity Score based on 28 joints-erythrocyte sedimentation rate; DMARD,
disease-modifying antirheumatic drug; HAQ-DI, Health Assessment
Questionnaire-disability index; MTX, methotrexate; PBO, placebo; RA, rheumatoid
arthritis.
Figure 1 Patient disposition and
study ﬂow chart. ITT, intention-to-treat;
MTX, methotrexate; PBO, placebo;
TCZ, tocilizumab.
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63.6% of switch patients did not exhibit radiographic progres-
sion at week 52.
DMARD and corticosteroid use
A comparable proportion of patients in both treatment arms
received additional conventional DMARDs at week 24 or later
(ﬁgure 2A; see online supplementary table S1). Some patients
with DAS28 just above 3.2 at week 24 did not add DMARDs.
Had the protocol been strictly followed, approximately 4%
more of the add-on patients and 9% more of the switch patients
would have added conventional DMARDs at week 24. By week
52, a total of 38 (14%) of add-on patients and 49 (18%) of
switch patients had added a further DMARD. Further, by week
52, the mean corticosteroid dose had changed from 6.8 mg/day
at baseline to 6.4 mg/day in the add-on arm and from 6.7 mg/
day at baseline to 6.3 mg/day in the switch arm.
Safety
Overall safety
An overview of the safety results is presented in table 3. Overall,
rates per 100 patient-years (PYs) of AEs, SAEs and SIs were
similar between groups. SAEs occurring in more than one
patient were congestive heart failure (0.7% (two patients) and
0.4% (one patient) in the add-on and switch groups, respect-
ively), tendon rupture (0% and 0.7% (two patients), respect-
ively), pneumonia (0% and 0.7% (two patients), respectively),
septic shock (0.7% (two patients) and 0%, respectively),
increased transaminases (0.4% (one patient) in both groups),
anaemia (0.4% (one patient) in both groups) and anxiety (0.4%
(one patient) in both groups). Additionally, there were four
deaths in the ﬁrst 52 weeks of the study, two in each study arm.
The causes of death in these four patients were (1) sepsis
(add-on group); (2) septic shock preceded by scrotal abscess,
skin necrosis, acute renal failure and congestive heart failure
(add-on group); (3) myocardial infarction (switch group) and
(4) sepsis with meningitis (switch group).
Through week 52, SIs had occurred at the rate of 4.5 and 5.5
per 100 PYs for the add-on and switch groups, respectively.
From baseline to week 24, the SI rate was 6.27 and 5.61 for the
add-on and switch groups, respectively; and 2.88 and 5.33 from
week 24 to week 52.
Immunogenicity
Valid immunogenicity data (baseline and postbaseline) were
available for 86.3% of add-on patients (239) and 80.8% (223)
of switch patients. The rate of overall and neutralising antidrug
antibodies (seroconversion in neutralising assay) was similar in
both treatment groups (table 3).
DISCUSSION
At week 52 of the ACT-RAY study, the analyses conﬁrmed the
sustainability of the suppression of disease activity observed at
Table 2 Efficacy results at weeks 24 and 52
Week 24 Week 52
Variable Add-on (N=277)
Switch
(N=276)
Between group
p value
Add-on
(N=277)
Switch
(N=276)
Between group
p value
DAS28 remission rate, % 40.4 34.8 0.21 45.5 36.6 0.03
Change in DAS28, mean (SD) −3.43 (1.326) −3.21 (1.305) 0.05 −3.74 (1.406) −3.67 (1.291) 0.39
LDAS, % 61.7 51.4 0.03 62.5 57.2 0.12
EULAR good/moderate responders, % 89.5 86.2 0.03 84.5 78.2 0.12
ACR-EULAR Boolean remission rate, % 6.9 5.4 0.53 17.7 12.3 0.09
SDAI remission rate (≤3.3), % 11.9 9.8 0.56 24.2 18.1 0.10
CDAI remission rate (≤2.8), % 11.9 7.6 0.12 22.7 15.9 0.06
Change in patient’s global assessment
of disease activity, mean (SD)
−34.3 (25.68) −32.4 (24.34) 0.31 −38.9 (25.59) −40.9 (26.21) 0.29
Change in physician’s global
assessment of disease activity, mean
(SD)
−40.7 (19.50) −38.5 (21.65) 0.25 −44.2 (21.10) −44.7 (21.40) 0.88
Change in patient’s global assessment
of pain, mean (SD)
−29.3 (26.64) −29.8 (24.92) 0.97 −33.1 (26.93) −38.4 (25.54) 0.03
Change in RAQoL, mean (SD) −6.07 (8.01) −5.19 (7.06) 0.27 −7.28 (8.14) −6.33 (7.69) 0.20
Fatigue,* % 51.3 50.0 0.68 39.7 32.7 -
Change in HAQ-DI, mean (SD) −0.56 (0.666) −0.55 (0.531) 0.93 −0.59 (0.713) −0.67 (0.630) 0.14
Change in ESR, mean (SD) −30.60 (24.187) −29.10 (24.518) 0.52 −31.81 (23.025) −31.18 (24.527) 0.77
Change in CRP, mean (SD) −1.37 (2.043) −1.39 (2.206) 0.61 −1.39 (1.943) −1.40 (2.216) 0.68
Change in total GSS, adjusted mean
(SEM)
0.18 (0.161) 0.35 (0.152) 0.20 0.35 (0.370) 0.63 (0.350) 0.36
Change in JSN score, adjusted mean
(SEM)
0.16 (0.121) 0.19 (0.115) 0.71 0.45 (0.314) 0.39 (0.297) 0.81
Change in erosion score, adjusted mean
(SEM)
0.03 (0.077) 0.15 (0.072) 0.044 −0.09 (0.125) 0.25 (0.118) 0.001
Patients with no progression in GSS
(≤1.5), %
91.3 88 0.22 92.8 86.1 0.016
*Assessed by the proportion of patients answering ‘yes’ to question 21 of the Rheumatoid Arthritis Quality of Life questionnaire (‘I feel tired whatever I do’).
ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; DAS28, Disease Activity Score based on 28 joints; DMARD, disease-modifying
antirheumatic drug; ESR; erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; GSS, Genant-modified Sharp score; HAQ-DI; Health Assessment
Questionnaire-disability index; JSN, joint space narrowing; LDAS, low-disease activity score; PBO, placebo; RA, rheumatoid arthritis; RAQoL, Rheumatoid Arthritis Quality of Life
questionnaire; SDAI, Simplified Disease Activity Index; SDC, smallest detectable change; SJC, swollen joint count; TCZ, tocilizumab; TJC, tender joint count.
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week 24 with tocilizumab when used either as monotherapy
after discontinuing methotrexate or in combination with metho-
trexate (with or without the addition of open-label DMARDs).
The ﬁrst 24 weeks of the ACT-RAY study compared the tocili-
zumab add-on and switch-to-monotherapy strategies in patients
with inadequate or incomplete response to methotrexate. Week
24 marked the beginning of the treat-to-target concept, with
treatment changes determined by disease activity. Because of the
introduction of conventional DMARDs, the week 52 results do
not represent a pure assessment of tocilizumab monotherapy
versus combination therapy with methotrexate but include the
growing effects of a treat-to-target strategy consistently applied
to both study arms.
The changes in non-tocilizumab therapies from week 24 com-
plicate the interpretation of the switch versus the add-on
concept. The disease activity-dependent addition of open-label
conventional DMARDs (of the investigator’s choice) from week
24 was mandated by the study protocol. In the absence of an
appropriate control and because the addition of the DMARD
was possible at different times, the effectiveness of this interven-
tion cannot be properly assessed and isolated from other effects,
such as late response to the study treatments. Reducing the cor-
ticosteroid dose was also possible but only within predeﬁned
limits to minimise any between-group differences that cortico-
steroid dose reductions could have on structural outcomes. Both
the addition of conventional DMARDs (other than methotrex-
ate) and the dose reduction of corticosteroids occurred in
similar proportions of patients in the add-on and switch arms.
Improvements in signs and symptoms of RA observed at week
24 were maintained or further improved up to week 52 in both
treatment groups. Results pointed towards a slightly more
favourable response for the add-on arm as numerical trends
were observed for most clinical and radiographic endpoints. In
exploratory analyses, statistical signiﬁcance in favour of the
add-on arm was identiﬁed for 4 of 18 endpoints, including clin-
ical and radiographic endpoints.
The addition of DMARDs according to disease activity in
both arms was expected to lead to a ‘dilution’ of potential dis-
tinctions between the two arms, resulting in smaller differences
at week 52 than at week 24, as seen with other treat-to-target
approaches.19 However, for the progression of structural
damage, a difference was hardly visible at week 24 but emerged
more clearly by week 52, possibly suggesting methotrexate as a
causative factor. On the other hand, the cumulative distribution
plot (ﬁgure 3C) demonstrates that, overall, only a few patients
beneﬁted from continuously receiving methotrexate.
Antidrug antibodies and neutralising antibodies were detected
in similar proportions of patients in the two groups. The inter-
pretation of this analysis is limited by the fact that the immuno-
genicity testing was introduced after the trial had started, and
not all patients could be included. As antidrug antibody positiv-
ity rates are very low compared with other biologics,20–22 these
data suggest that the immunogenic potential of tocilizumab
could be low. However, these results do not exclude the risk of
serious hypersensitivity reactions.23
Other safety outcomes were consistent between the two study
groups, except that the add-on strategy resulted in a numerically
higher proportion of patients who had transaminase level
increases compared with the switch strategy. This trend was also
observed at week 24 and in other tocilizumab clinical trials,
including ACT-STAR and ACT-SURE.16 24 25 These observations
suggest that methotrexate and tocilizumab may have an additive
effect on liver transaminases, the clinical relevance of which
remains unclear. Overall, the incidence of events such as SAEs,
SIs and discontinuations was similar between the strategies and
consistent with previous tocilizumab studies.
Both the add-on and the switch strategies (with or without
additional DMARDs) led to meaningful clinical and radio-
graphic responses that could be maintained and, in some
cases, improved upon in the ﬁrst year of treatment. While
there was no major overall difference between the add-on and
switch treatment strategies, ACT-RAY provides useful
Figure 2 Efﬁcacy results. (A) Percentage of patients receiving additional conventional disease-modifying antirheumatic drugs (DMARDs) between
weeks 24 and 52. Results over time for (B) mean DAS28, (C) percentage of patients achieving ACR20, ACR50, ACR70 and ACR90, and (D) mean
change from baseline in SJC and TJC. ACR, American College of Rheumatology; DAS28, Disease Activity Score based on 28 joints; DMARD,
disease-modifying antirheumatic drug; TJC, tender joint count; SJC, swollen joint count. p values are for week 24 and week 52 intergroup data,
respectively.
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information for clinical decision making on a per-patient
basis. For example, the addition of tocilizumab to methotrex-
ate may be the preferred approach in patients who can
tolerate methotrexate as per EULAR treatment recommenda-
tions.26 However, for patients who cannot be treated with
methotrexate, a switch to tocilizumab monotherapy is an
option that may provide a robust level of disease control.
Examination of other sets of patients with RA (including
registries) will be necessary to conﬁrm and further corrobor-
ate the results reported herein.
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Figure 3 Radiographic results. (A) Mean change from baseline in
total Genant-modiﬁed Sharp score (GSS), (B) patients without
radiographic progression and (C) cumulative distribution plot of change
from baseline to week 52 in total GSS. Area between grey lines is
within SDC. GSS ≤1.5; patients without an assessment classiﬁed as
progressors, p values from Cochran–Mantel–Haenszel χ2 tests with
strata deﬁned by baseline score quartile and baseline DAS28 ≤ or
>5.5; error bars=SE of the mean; baseline annualised progression rate
was GSS divided by RA duration. DAS28, Disease Activity Score based
on 28 joints; GSS, Genant-modiﬁed Sharp score; RA, rheumatoid
arthritis. SDC, smallest detectable change.
Table 3 Overview of adverse events, deaths, liver enzyme
elevations and antitocilizumab antibodies until week 52
Add-on (N=277) Switch (N=276)
Total TCZ exposure 247.3 237.8
Adverse events (AE)
Total patients with ≥1 AE,
% (n)
83.0% (230) 83.0% (229)
Total number of AEs 1075 984
Rate of AEs (per 100 PY;
95% CI)
403.6 (379.9 to 428.5) 384.20 (360.6 to 409.0)
≥1 AE leading to treatment
discontinuation, % (n)
7.6 (21) 6.5 (18)
≥1 AE leading to dose
modification or
interruption, % (n)
39.4 (109) 31.2 (86)
≥1 AE leading to
withdrawal, % (n)
6.9 (19) 5.8 (16)
Serious adverse events (SAEs)
Total patients with ≥1 SAE,
% (n)
7.9% (22) 9.8% (27)
Total number of SAEs 30 43
Rate of SAEs (per 100 PY;
95% CI)
11.3 (7.6 to 16.1) 16.8 (12.2 to 22.6)
Serious infections (SIs)
Total patients with ≥1 SI,
% (n)
3.6% (10) 2.9% (8)
Total number of SIs 12 14
Rate of SIs (per 100 PY;
95% CI)
4.5 (2.3 to 7.9) 5.5 (3.0 to 9.2)
Total number of deaths 2 2
ALT elevations, % (n) N*=244 N*=242
>ULN†-1.5×ULN 27% (67) 17% (41)
>1.5×ULN-3×ULN 25% (60) 14% (35)
>3×ULN-5×ULN 8% (19) 2% (6)
>5×ULN 3% (8) <1% (1)
AST elevations, % (n) N*=257 N*=249
>ULN‡-1.5×ULN 30% (78) 17% (43)
>1.5×ULN-3×ULN 16% (41) 6% (16)
>3×ULN-5×ULN 3% (7) 1% (2)
>5×ULN <1% (1) 0
Antitocilizumab antibodies
postbaseline,§ % (n)
N=239 N=223
Detection of antidrug
antibodies
1.5% (4) 2.2% (6)
Detection of neutralising
antidrug antibodies
0.7% (2) 1.8% (5)
*Number of patients with normal values at baseline.
†ULN=55 U/L for ALT.
‡ULN=40 U/L for AST.
§The cut-off for assay positivity was determined using baseline sera from ACT-RAY
patients.
ALT, alanine aminotransferase (GPT); AST, aspartate aminotransferase (GOT);
PY, patient-years; TCZ, tocilizumab; ULN, upper limit of normal.
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